News

Stem cell-derived conditioned medium, or the liquid that remains after cells are cultured, reduces the signs of pulmonary arterial hypertension (PAH) in rat and cell models, a study showed. “These findings support [stem cell]‐derived conditioned medium as a promising therapeutic strategy for PAH, warranting further investigation in translational studies…

Gossamer Bio is moving toward acquiring Respira Therapeutics and its lead treatment candidate, RT234, an inhaled therapy being developed for the on-demand treatment of pulmonary hypertension (PH). The two companies entered into an option agreement that gives Gossamer the exclusive right to this acquisition within an agreed-upon…

For pregnant women with pulmonary hypertension (PH), higher pulmonary arterial pressure — blood pressure levels in the blood vessels that supply the lungs — is associated with longer hospital stays and a greater chance of being admitted to the intensive care unit (ICU). That’s according to a new study…

Underweight infants with pulmonary hypertension (PH) are at increased risk of developing retinopathy of prematurity (ROP), a leading cause of childhood blindness, according to a study. However, the prevalence of severe ROP was 18% lower in PH infants who received treatment with inhaled nitric oxide (iNO). “While iNO is…

The European Patent Office has given Tenax Therapeutics notice that it plans to grant a patent covering the use of levosimendan and its active metabolites to treat pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), the company said. TNX-103, an oral formulation currently in Phase…

Allrock Bio has raised $50 million in financing to support the clinical development of pulmonary hypertension (PH) treatment ROC-101. The company said it will use the funds to launch a Phase 2a clinical trial to test ROC-101 in people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated…

Phaware, a global advocacy organization, is launching a special podcast series to raise awareness of pulmonary arterial hypertension (PAH) caused by the use of methamphetamine, a stimulant drug known for its psychoactive effects. Methamphetamine-induced PAH is now known simply as Meth-PAH. The six-episode series, part of the “…

Pulmonary endarterectomy (PEA), a surgery to remove blood clots in individuals with chronic thromboembolic pulmonary hypertension (CTEPH), may be more effective in improving pulmonary circulation and heart function than balloon pulmonary angioplasty (BPA), according to a recent study. After treatment, a higher proportion of patients in the BPA group…

Stanford University has been awarded a grant from the U.S. National Institutes of Health (NIH) to begin a Phase 2 clinical trial of pulmonary arterial hypertension (PAH) treatment tiprelestat, the treatment’s developer announced. Tiakis Biotech said tiprelestat was found to be safe in earlier clinical trials involving more…

Corvista Health’s point-of-care device can detect cases of pulmonary hypertension (PH) that other noninvasive diagnostic tools miss, according to a recent case series. “By enabling physicians to identify pulmonary hypertension within minutes, non-invasively, and even when traditional tests fail, we are offering a new standard of care that…

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to mosliciguat, an investigational inhalation therapy that Pulmovant is developing to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The MHLW gives this designation to experimental medicines intended to treat conditions affecting fewer than…

People with pulmonary hypertension (PH) face significant obstacles when seeking timely care, with barriers arising at each stage from symptom onset through diagnosis and treatment, according to interviews with patients and healthcare providers. Those barriers included a lack of PH knowledge among non-specialists, symptoms being dismissed, and limited access…